Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPN14770 open-label extension in Fragile X Syndrome
NCT05367960Phase 3Active, not recruiting
- Sponsor
- Tetra Therapeutics
- Start
- Nov 2022
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zatolmilast in Fragile X syndrome (FXS), sponsored by Tetra Therapeutics. Primary endpoint: Safety and tolerability of BPN14770 at 24 months. Started Nov 2022; status: active, not recruiting.
02
Drugs
zatolmilast
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT05367960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05367960.